- Home
- TRVI vs CBLL Comparison
TRVI vs CBLL Comparison
Compare TRVI & CBLL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TRVI
- CBLL
- Stock Information
- Founded
- TRVI 2011
- CBLL 2014
- Country
- TRVI United States
- CBLL United States
- Employees
- TRVI N/A
- CBLL N/A
- Industry
- TRVI Biotechnology: Pharmaceutical Preparations
- CBLL
- Sector
- TRVI Health Care
- CBLL
- Exchange
- TRVI Nasdaq
- CBLL Nasdaq
- Market Cap
- TRVI 725.7M
- CBLL 710.2M
- IPO Year
- TRVI 2019
- CBLL 2024
- Fundamental
- Price
- TRVI $6.89
- CBLL $15.80
- Analyst Decision
- TRVI Strong Buy
- CBLL Strong Buy
- Analyst Count
- TRVI 9
- CBLL 6
- Target Price
- TRVI $19.94
- CBLL $33.00
- AVG Volume (30 Days)
- TRVI 1.6M
- CBLL 363.3K
- Earning Date
- TRVI 08-07-2025
- CBLL 08-14-2025
- Dividend Yield
- TRVI N/A
- CBLL N/A
- EPS Growth
- TRVI N/A
- CBLL N/A
- EPS
- TRVI N/A
- CBLL N/A
- Revenue
- TRVI N/A
- CBLL $71,535,000.00
- Revenue This Year
- TRVI N/A
- CBLL $33.98
- Revenue Next Year
- TRVI N/A
- CBLL $28.82
- P/E Ratio
- TRVI N/A
- CBLL N/A
- Revenue Growth
- TRVI N/A
- CBLL 44.86
- 52 Week Low
- TRVI $2.36
- CBLL $10.01
- 52 Week High
- TRVI $7.48
- CBLL $32.75
- Technical
- Relative Strength Index (RSI)
- TRVI 64.54
- CBLL N/A
- Support Level
- TRVI $5.41
- CBLL N/A
- Resistance Level
- TRVI $6.08
- CBLL N/A
- Average True Range (ATR)
- TRVI 0.32
- CBLL 0.00
- MACD
- TRVI 0.14
- CBLL 0.00
- Stochastic Oscillator
- TRVI 89.91
- CBLL 0.00
About TRVI Trevi Therapeutics Inc.
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release formulation of nalbuphine.
About CBLL CeriBell Inc. Common Stock
CeriBell Inc is a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. The Company has developed the Ceribell System, a novel, point-of-care electroencephalography (EEG) platform specifically designed to address the unmet needs of patients in the acute care setting. By combining proprietary, portable and rapidly deployable hardware with sophisticated artificial intelligence (AI) powered algorithms, the Ceribell System enables rapid diagnosis and continuous monitoring of patients with neurological conditions.